Q32 Bio Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
QTTB Nasdaq 2834 www.q32bio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Q32 Bio Inc.

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 10:59 am
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - Apr 30th, 2025 10:59 am
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - Apr 16th, 2025 10:59 am
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - Mar 11th, 2025 10:59 am
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - Mar 8th, 2025 4:00 pm
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - Feb 28th, 2025 2:00 pm
Q32 Bio to Participate in Upcoming March Investor Conferences - Feb 26th, 2025 11:59 am
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata - Feb 10th, 2025 9:05 pm
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Feb 4th, 2025 9:05 pm
Q32 Bio price target lowered to $20 from $80 at Oppenheimer - Dec 12th, 2024 12:45 pm
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment - Dec 11th, 2024 9:11 pm
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program - Dec 10th, 2024 9:05 pm
Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30% - Dec 4th, 2024 11:48 am
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 7th, 2024 11:59 am
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - Nov 5th, 2024 11:59 am
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 - Oct 14th, 2024 10:59 am
Q32 Bio to Participate in Upcoming September Investor Conferences - Aug 29th, 2024 10:59 am
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis - Jul 9th, 2024 10:59 am
Q32 Bio Joins Russell 3000® Index - Jul 1st, 2024 10:59 am
Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake - Jun 27th, 2024 11:05 am